Alzamend Neuro, Inc. ALZN
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Alzamend Neuro, Inc. (ALZN) is a healthcare company listed in the US with a market value of about $6M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -373%.
About Alzamend Neuro
Alzamend Neuro is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 7 years in our data. Its share count rose by 4582% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$9M | -$5M | -$10M | -$15M | -$12M | -$5M | -$4M |
| Free cash flow | — | — | — | -$9M | -$7M | — | — |
| EPS (diluted) | $-2.63 | $-11.32 | $-132.33 | $-208.79 | $-191.55 | $-95.77 | $-82.09 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -944.6% | -89.5% | — | -385.7% | -72.9% | -166.6% | -425.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Alzamend Neuro pay a dividend?
Not currently.
Is Alzamend Neuro a good stock to buy?
We do not give buy or sell advice. Alzamend Neuro scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.